At the news
? NEUTRALIMPACT 2/10 144 filed Jun 24, 2026 at 16:37 ET
Director Leonard Post filed a Form 144 notice of intent to sell 5,000 shares of CG Oncology common stock, with an estimated aggregate market value of $328,650. The shares are to be acquired through the exercise of stock options, and the sale is planned under a Rule 10b5-1 trading plan. This is a routine insider sale by a director, not a top executive, and the dollar amount is small relative to the company's $6.1B market cap.
- Director Leonard Post filed Form 144 on June 24, 2026, indicating intent to sell 5,000 shares.
- Estimated aggregate market value of the proposed sale is $328,650.
- Shares are to be acquired upon exercise of stock options; sale is part of a pre-arranged 10b5-1 plan.
- The sale represents a tiny fraction of the company's $6.1B market cap.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access